Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Prostate Cancer

Free Subscription Articles published in Proc Natl Acad Sci U S A Retrieve available abstracts of 16 articles: HTML format

Single Articles

July 2025
1. HE D, Zhang L, Yu L, Zhang Y, et al
   Fine structural design of 3betaHSD1 inhibitors for prostate cancer therapy.
   Proc Natl Acad Sci U S A. 2025;122:e2422267122.
   PubMed     Abstract available
   
   
   
2. SUSHENTSEV N, Hamm G, Manavaki R, McLean MA, et al
   Spatial metabolomics informs the use of clinical imaging for improved detection of cribriform prostate cancer.
   Proc Natl Acad Sci U S A. 2025;122:e2502423122.
   PubMed     Abstract available
   
   
   June 2025
3. PAPPAS K, Ferrari M, Smith P, Nandakumar S, et al
   BRCA2 reversion mutation-independent resistance to PARP inhibition through impaired DNA prereplication complex function.
   Proc Natl Acad Sci U S A. 2025;122:e2426743122.
   PubMed     Abstract available
   
   
   April 2025
4. 
   Correction for Pitzen et al., Comparative transcriptomics reveals a mixed basal, club, and hillock epithelial cell identity in castration-resistant prostate cancer.
   Proc Natl Acad Sci U S A. 2025;122:e2504762122.
   PubMed    
   
   
   March 2025
5. LEE J, Park J, Hur Y, Um D, et al
   ETV5 reduces androgen receptor expression and induces neural stem-like properties during neuroendocrine prostate cancer development.
   Proc Natl Acad Sci U S A. 2025;122:e2420313122.
   PubMed     Abstract available
   
   
   February 2025
6. PITZEN SP, Rudenick AN, Qiu Y, Zhang W, et al
   Comparative transcriptomics reveals a mixed basal, club, and hillock epithelial cell identity in castration-resistant prostate cancer.
   Proc Natl Acad Sci U S A. 2025;122:e2415308122.
   PubMed     Abstract available
   
   
   December 2024
7. VARUZHANYAN G, Chen CC, Freeland J, He T, et al
   PGC-1alpha drives small cell neuroendocrine cancer progression toward an ASCL1-expressing subtype with increased mitochondrial capacity.
   Proc Natl Acad Sci U S A. 2024;121:e2416882121.
   PubMed     Abstract available
   
   
   November 2024
8. KOHRT SE, Novak EJ, Tapadar S, Wu B, et al
   Small-molecule disruption of androgen receptor-dependent chromatin clusters.
   Proc Natl Acad Sci U S A. 2024;121:e2406239121.
   PubMed     Abstract available
   
   
   October 2024
9. WANG Z, Yu H, Bao W, Qu M, et al
   Proteomic and phosphoproteomic landscape of localized prostate cancer unveils distinct molecular subtypes and insights into precision therapeutics.
   Proc Natl Acad Sci U S A. 2024;121:e2402741121.
   PubMed     Abstract available
   
   
   September 2024
10. SU XA, Stopsack KH, Schmidt DR, Ma D, et al
    RAD21 promotes oncogenesis and lethal progression of prostate cancer.
    Proc Natl Acad Sci U S A. 2024;121:e2405543121.
    PubMed     Abstract available
    
    
    August 2024
11. YU G, Corn PG, Mak CSL, Liang X, et al
    Prostate cancer-induced endothelial-cell-to-osteoblast transition drives immunosuppression in the bone-tumor microenvironment through Wnt pathway-induced M2 macrophage polarization.
    Proc Natl Acad Sci U S A. 2024;121:e2402903121.
    PubMed     Abstract available
    
    
    July 2024
12. PORNOUR M, Jeon HY, Ryu H, Khadka S, et al
    USP11 promotes prostate cancer progression by up-regulating AR and c-Myc activity.
    Proc Natl Acad Sci U S A. 2024;121:e2403331121.
    PubMed     Abstract available
    
    
    
13. ZAIDI S, Park J, Chan JM, Roudier MP, et al
    Single-cell analysis of treatment-resistant prostate cancer: Implications of cell state changes for cell surface antigen-targeted therapies.
    Proc Natl Acad Sci U S A. 2024;121:e2322203121.
    PubMed     Abstract available
    
    
    April 2024
14. HE T, Cheng C, Qiao Y, Cho H, et al
    Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer.
    Proc Natl Acad Sci U S A. 2024;121:e2322563121.
    PubMed     Abstract available
    
    
    December 2023
15. SUSHENTSEV N, Hamm G, Richings J, McLean MA, et al
    Imaging tumor lactate is feasible for identifying intermediate-risk prostate cancer patients with postsurgical biochemical recurrence.
    Proc Natl Acad Sci U S A. 2023;120:e2312261120.
    PubMed     Abstract available
    
    
    November 2023
16. MAJI S, Pradhan AK, Kumar A, Bhoopathi P, et al
    MDA-9/Syntenin in the tumor and microenvironment defines prostate cancer bone metastasis.
    Proc Natl Acad Sci U S A. 2023;120:e2307094120.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.